Abbvie Inc Stock Cash And Equivalents

ABBV Stock

USD 176.95 5.22 3.04%

AbbVie Inc fundamentals help investors to digest information that contributes to AbbVie's financial success or failures. It also enables traders to predict the movement of AbbVie Stock. The fundamental analysis module provides a way to measure AbbVie's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AbbVie stock.

Other Current Liab Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

AbbVie Inc Company Cash And Equivalents Analysis

AbbVie's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Cash

Bank Deposits

+

Liquidities

More About Cash And Equivalents | All Equity Analysis

Current AbbVie Cash And Equivalents

11.88 B

Most of AbbVie's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AbbVie Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

AbbVie Cash And Equivalents Driver Correlations

Understanding the fundamental principles of building solid financial models for AbbVie is extremely important. It helps to project a fair market value of AbbVie Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since AbbVie's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of AbbVie's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of AbbVie's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Accounts Payable	Net Receivables	Good Will	Short Term Investments	Total Liab	Total Current Assets	Intangible Assets	Property Plant Equipment	Long Term Debt	Short Term Debt	Common Stock	Net Tangible Assets	Retained Earnings	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Treasury Stock	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock	Current Deferred Revenue
Total Assets		0.35	0.96	0.81	0.93	0.99	-0.4	0.99	0.66	0.97	0.95	0.94	0.78	-0.56	-0.96	0.09	0.95	0.86	0.45	0.02	-0.13	0.63	0.88	-0.32	-0.2	0.33
Total Stockholder Equity	0.35		0.29	0.26	0.46	0.4	-0.26	0.19	-0.24	0.48	0.47	0.07	0.22	0.26	-0.32	-0.21	0.15	0.04	0.1	-0.28	0.75	0.36	0.54	-0.6	-0.08	0.13
Net Debt	0.96	0.29		0.74	0.84	0.96	-0.28	0.95	0.52	0.98	0.89	0.93	0.79	-0.57	-0.96	0.12	0.9	0.82	0.54	0.13	-0.15	0.64	0.85	-0.41	-0.12	0.2
Accounts Payable	0.81	0.26	0.74		0.85	0.83	-0.43	0.8	0.54	0.76	0.81	0.73	0.65	-0.59	-0.87	-0.24	0.79	0.83	0.43	0.02	-0.11	0.51	0.73	-0.46	-0.69	0.68
Net Receivables	0.93	0.46	0.84	0.85		0.95	-0.39	0.89	0.56	0.9	0.97	0.78	0.7	-0.47	-0.87	-0.07	0.83	0.79	0.28	-0.13	0.05	0.61	0.83	-0.46	-0.29	0.48
Good Will	0.99	0.4	0.96	0.83	0.95		-0.38	0.97	0.57	0.98	0.97	0.89	0.77	-0.53	-0.96	0.05	0.91	0.86	0.47	0.04	-0.09	0.63	0.86	-0.43	-0.22	0.38
Short Term Investments	-0.4	-0.26	-0.28	-0.43	-0.39	-0.38		-0.37	-0.36	-0.35	-0.43	-0.33	-0.42	0.44	0.39	0.18	-0.46	-0.44	-0.02	0.34	0.01	-0.33	-0.45	0.03	0.24	-0.24
Total Liab	0.99	0.19	0.95	0.8	0.89	0.97	-0.37		0.73	0.93	0.92	0.97	0.78	-0.63	-0.95	0.13	0.96	0.89	0.45	0.06	-0.27	0.6	0.83	-0.23	-0.19	0.33
Total Current Assets	0.66	-0.24	0.52	0.54	0.56	0.57	-0.36	0.73		0.47	0.54	0.77	0.45	-0.55	-0.56	0.21	0.77	0.65	0.14	-0.11	-0.51	0.3	0.52	0.41	-0.19	0.3
Intangible Assets	0.97	0.48	0.98	0.76	0.9	0.98	-0.35	0.93	0.47		0.94	0.88	0.78	-0.49	-0.95	0.07	0.88	0.79	0.5	0.05	0.0	0.66	0.89	-0.48	-0.14	0.25
Property Plant Equipment	0.95	0.47	0.89	0.81	0.97	0.97	-0.43	0.92	0.54	0.94		0.82	0.77	-0.44	-0.9	-0.14	0.88	0.8	0.31	-0.12	0.06	0.68	0.88	-0.47	-0.26	0.48
Long Term Debt	0.94	0.07	0.93	0.73	0.78	0.89	-0.33	0.97	0.77	0.88	0.82		0.7	-0.64	-0.91	0.2	0.96	0.83	0.49	0.06	-0.36	0.51	0.81	-0.08	-0.15	0.21
Short Term Debt	0.78	0.22	0.79	0.65	0.7	0.77	-0.42	0.78	0.45	0.78	0.77	0.7		-0.48	-0.79	-0.03	0.75	0.73	0.2	0.07	-0.1	0.91	0.72	-0.42	-0.18	0.25
Common Stock	-0.56	0.26	-0.57	-0.59	-0.47	-0.53	0.44	-0.63	-0.55	-0.49	-0.44	-0.64	-0.48		0.57	-0.18	-0.6	-0.76	-0.51	-0.31	0.43	-0.19	-0.34	0.07	0.19	-0.19
Net Tangible Assets	-0.96	-0.32	-0.96	-0.87	-0.87	-0.96	0.39	-0.95	-0.56	-0.95	-0.9	-0.91	-0.79	0.57		-0.01	-0.92	-0.85	-0.5	-0.09	0.16	-0.64	-0.88	0.42	0.36	-0.35
Retained Earnings	0.09	-0.21	0.12	-0.24	-0.07	0.05	0.18	0.13	0.21	0.07	-0.14	0.2	-0.03	-0.18	-0.01		0.01	0.09	0.22	0.51	-0.5	-0.17	-0.16	0.42	0.62	-0.63
Long Term Debt Total	0.95	0.15	0.9	0.79	0.83	0.91	-0.46	0.96	0.77	0.88	0.88	0.96	0.75	-0.6	-0.92	0.01		0.88	0.42	-0.04	-0.27	0.55	0.85	-0.13	-0.28	0.38
Capital Surpluse	0.86	0.04	0.82	0.83	0.79	0.86	-0.44	0.89	0.65	0.79	0.8	0.83	0.73	-0.76	-0.85	0.09	0.88		0.53	0.21	-0.38	0.43	0.63	-0.24	-0.32	0.45
Deferred Long Term Liab	0.45	0.1	0.54	0.43	0.28	0.47	-0.02	0.45	0.14	0.5	0.31	0.49	0.2	-0.51	-0.5	0.22	0.42	0.53		0.44	-0.21	-0.07	0.28	-0.21	-0.12	0.1
Long Term Investments	0.02	-0.28	0.13	0.02	-0.13	0.04	0.34	0.06	-0.11	0.05	-0.12	0.06	0.07	-0.31	-0.09	0.51	-0.04	0.21	0.44		-0.48	-0.09	-0.29	-0.09	0.05	-0.08
Treasury Stock	-0.13	0.75	-0.15	-0.11	0.05	-0.09	0.01	-0.27	-0.51	0.0	0.06	-0.36	-0.1	0.43	0.16	-0.5	-0.27	-0.38	-0.21	-0.48		0.14	0.2	-0.5	-0.01	0.02
Short Long Term Debt	0.63	0.36	0.64	0.51	0.61	0.63	-0.33	0.6	0.3	0.66	0.68	0.51	0.91	-0.19	-0.64	-0.17	0.55	0.43	-0.07	-0.09	0.14		0.69	-0.48	-0.17	0.23
Net Invested Capital	0.88	0.54	0.85	0.73	0.83	0.86	-0.45	0.83	0.52	0.89	0.88	0.81	0.72	-0.34	-0.88	-0.16	0.85	0.63	0.28	-0.29	0.2	0.69		-0.37	-0.3	0.27
Net Working Capital	-0.32	-0.6	-0.41	-0.46	-0.46	-0.43	0.03	-0.23	0.41	-0.48	-0.47	-0.08	-0.42	0.07	0.42	0.42	-0.13	-0.24	-0.21	-0.09	-0.5	-0.48	-0.37		0.31	-0.32
Capital Stock	-0.2	-0.08	-0.12	-0.69	-0.29	-0.22	0.24	-0.19	-0.19	-0.14	-0.26	-0.15	-0.18	0.19	0.36	0.62	-0.28	-0.32	-0.12	0.05	-0.01	-0.17	-0.3	0.31		-0.8
Current Deferred Revenue	0.33	0.13	0.2	0.68	0.48	0.38	-0.24	0.33	0.3	0.25	0.48	0.21	0.25	-0.19	-0.35	-0.63	0.38	0.45	0.1	-0.08	0.02	0.23	0.27	-0.32	-0.8

Click cells to compare fundamentals

Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).

Competition

Predict AbbVie

AbbVie Cash And Cash Equivalents Changes

Cash And Cash Equivalents Changes

(412.96 Million)

AbbVie reported Cash And Cash Equivalents Changes of (434.7 Million) in 2023

In accordance with the recently published financial statements, AbbVie Inc has 11.88 B in Cash And Equivalents. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The cash and equivalents for all United States stocks is significantly lower than that of the firm.

AbbVie Cash And Equivalents Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AbbVie's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AbbVie could also be used in its relative valuation, which is a method of valuing AbbVie by comparing valuation metrics of similar companies.

AbbVie is currently under evaluation in cash and equivalents category among its peers.

AbbVie ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, AbbVie's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to AbbVie's managers, analysts, and investors.

Environmental

Governance

Social

AbbVie Fundamentals

	Return On Equity	0.56
	Return On Asset	0.0772
	Profit Margin	0.09 %
	Operating Margin	0.29 %
	Current Valuation	376.49 B
	Shares Outstanding	1.77 B
	Shares Owned By Insiders	0.09 %
	Shares Owned By Institutions	73.43 %
	Number Of Shares Shorted	18.13 M
	Price To Earning	21.28 X
	Price To Book	51.84 X
	Price To Sales	5.63 X
	Revenue	54.32 B
	Gross Profit	41.53 B
	EBITDA	26.36 B
	Net Income	4.88 B
	Cash And Equivalents	11.88 B
	Cash Per Share	6.72 X
	Total Debt	59.38 B
	Debt To Equity	4.37 %
	Current Ratio	0.93 X
	Book Value Per Share	3.41 X
	Cash Flow From Operations	22.84 B
	Short Ratio	3.61 X
	Earnings Per Share	2.87 X
	Price To Earnings To Growth	0.42 X
	Target Price	204.74
	Number Of Employees	50 K
	Beta	0.61
	Market Capitalization	312.7 B
	Total Asset	134.71 B
	Retained Earnings	(1000 M)
	Working Capital	(4.84 B)
	Current Asset	16.31 B
	Current Liabilities	10.89 B
	Annual Yield	0.04 %
	Five Year Return	4.33 %
	Net Asset	134.71 B
	Last Dividend Paid	6.2

About AbbVie Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze AbbVie Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AbbVie using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AbbVie Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for AbbVie Stock Analysis

When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC